Rodman & Renshaw Downgrades Valeant Pharmaceuticals (VRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St steadies ahead of South Korean chip bellwether SK Hynix's debut
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
S&P Affirms Rating on Valeant Pharma (VRX) Amid Weak Q3 Report, Cut Outlook
November 8, 2016 12:17 PM ESTS&P Global Ratings said its ratings and outlook on Valeant Pharmaceuticals International Inc. (NYSE: VRX) (B/Stable/--) are unchanged following the company's weak earnings report for the third quarter and lowered guidance for 2016. The company also indicated 2017 performance will likely be weaker than in 2016, because of the loss of exclusivity on certain neurology products. This contrasts with our prior expectation that 2017 would be materially stronger than 2016, given that 2016 has been a year of significant turbulence and transition for the company.
This represents a significant deterioration from our expectations and we are lowering our... More
Valeant Pharma (VRX) Misses Q3 EPS by 20c, Cuts FY16 Outlook
November 8, 2016 6:02 AM ESTValeant Pharma (NYSE: VRX) reported Q3 EPS of $1.55, $0.20 worse than the analyst estimate of $1.75. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.49 billion.
"This past quarter, we made further progress toward establishing the new Valeant," said Joseph C.... More
